Heart failure & Diabetes: Time for a more unified approach
This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017
Video navigation menu
Diabetes is an important comorbidity in HF. 00:19
The results of the EMPA-REG OUTCOME trial suggest that empagliflozin may prevent the development of HF 01:44
Considering that HF was not an inclusion criterium in EMPA-REG OUTCOME trial, what can we say about the type of HF that some developed? 05:21
What do the ESC guidelines say about management of HF with diabetes? 07:21
Outstanding questions on the use of SGLT2 inhibitors for treatment of HF 08:04
Educational information
The educational objectives of this symposium were to:
- Summarise the epidemiology and pathophysiology of patients at increased cardiovascular risk and diabetes
- Identify key components of renal glucose handling and the contribution of the kidney to glucose homeostasis
- Describe the effect of multiple interventions that currently are deployed for T2D on cardiovascular safety and the currently unmet need on impacting cardiovascular outcomes
- Explain, based on scientific evidence, the effects that SGLT2 inhibiting agents may have on cardiometabolic markers, including lipids, weight gain, risk of hypoglycemia, HbA1c, glucose levels, related markers and cardiovascular outcomes
- Discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multi-risk patients
Faculty
Stefan D. Anker, MD is Professor of (Tissue)Homeostasis in Cardiology & Metabolism, Charité, Berlin, Germany
CME Accreditation
This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).
Disclosures
This symposium was supported by an unrestricted educational grant provided by Boehringer-Ingelheim/Lilly
Online-CME
This is available as accredited online CME for members. Click the button below to enroll:
EnrollThe information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: